A multicentre randomised phase III study of low-dose thalidomide, prednisolone and zoledronic acid versus prednisolone and zoledronic acid to assess survival post-ASCT maintenance therapy in patients with multiple myeloma (MM06)

Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study

doi : http://doi.org/10.1186/1472-6904-8-2

Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure

doi : http://doi.org/10.1200/JCO.2008.18.8573

Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma

doi : http://doi.org/10.3109/10428190903216804

Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial

doi : http://doi.org/10.3109/10428194.2012.664842

Maintenance Treatment and Survival in Patients With Myeloma

doi : http://doi.org/10.1001/jamaoncol.2018.2961

Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study

doi : http://doi.org/10.1016/S2352-3026(14)00022-2

Australasian Leukaemia And Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Australasian Leukaemia and Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326